31 Kazia Theraputics Limited Annual Report 2022 2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports Short-term benefits Postemployment benefits Sharebased payments Movements in accrued leave Nonmonetary Salary & fees Cash Bonus Cash Super- annuation Options Equity- settled Total 2021 $ $ $ $ $ $ Non-Executive Directors: I Ross* 147,436 20,000 - - 119,067 286,503 B Carmine 82,500 22,500 - 9,975 119,067 234,042 S Coffey 82,500 22,500 - 9,975 119,067 234,042 Executive Directors: J Garner 503,000 240,000 90,400 70,585 228,651 1,132,636 Other Key Management Personnel: G Heaton 204,000 25,000 (241) 21,755 15,069 265,583 K Hill 108,525 26,400 - - 15,677 150,602 1,127,961 356,400 90,159 112,290 616,598 2,303,408 * Salary paid in UK pounds, but disclosed in Australian dollars using a conversion rate of 0.5562 The relative proportions of remuneration that are linked to performance and those that are at risk Fixed remuneration At risk - STI At risk - LTI Name 2022 2021 2022 2021 2022 2021 Non-Executive Directors: I Ross 77% 51% - 7% 23% 42% B Carmine 67% 40% - 10% 33% 50% S Coffey 67% 40% - 10% 33% 50% Executive Directors: J Garner 33% 59% 16% 21% 51% 20% Other Key Management Personnel: J Friend 52% - 21% - 27% - K Krumeich 75% - - - 25% - G Heaton 71% 85% 15% 9% 14% 6% K Hill 80% 72% 9% 18% 11% 10% Consequences of performance on shareholder wealth Shareholder wealth in a company engaged in drug development is best delivered through retention of KMPs with an expert level of knowledge of our drug candidates. Non performance vesting options best deliver this value to investors, through driving an increased retention of KMPs. The directors have selected a CEO and key management team who, in the directors opinion, are well placed to realise such an outcome for our shareholders. June 2016 June 2017 June 2018 June 2019 June 2020 June 2021 June 2022 Enterprise Value 6,451,958 8,704,373 13,496,157 15,715,234 34,751,206 145,349,234 77,973,444 Total bonuses paid to KMP 38,967 191,135 - 125,400 212,500 356,400 577,978 Number of bonus participants 4 5 - 3 3 6 4 Share options issued to KMP 8,800,000 450,000 362,000 100,000 1,300,000 2,100,000 4,300,000 Number of KMP granted options 3 2 2 2 3 6 5 Our Collaborators
RkJQdWJsaXNoZXIy MjE2NDg3